Terms: = Leukemia AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR AND Staging
4 results:
1. Role of FDG PET/CT in Patients With Lymphoma Treated With Chimeric Antigen Receptor T-Cell Therapy: Current Concepts.
Murad V; Kohan A; Ortega C; Prica A; Veit-Haibach P; Metser U
AJR Am J Roentgenol; 2024 Mar; 222(3):e2330301. PubMed ID: 38054958
[TBL] [Abstract] [Full Text] [Related]
2. cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma.
Lee DH; Kumar A; Mohammed T; Peres LC; Alsina M; Bachmeier C; Blue BJ; Brayer J; Chandrasekhar S; Grajales Cruz A; De Avila G; Elmariah H; Faramand R; Freeman C; Jain M; Khadka S; Khimani F; Liu H; Nishihori T; Oswald LB; Castaneda Puglianini OA; Shain KH; Smith E; Baz RC; Locke FL; Oliveira GH; Alomar M; Hansen DK
Blood Adv; 2023 Aug; 7(16):4247-4257. PubMed ID: 37307173
[TBL] [Abstract] [Full Text] [Related]
3. Advanced Flow Cytometry Assays for Immune Monitoring of car-T Cell Applications.
Blache U; Weiss R; Boldt A; Kapinsky M; Blaudszun AR; Quaiser A; Pohl A; Miloud T; Burgaud M; Vucinic V; Platzbecker U; Sack U; Fricke S; Koehl U
Front Immunol; 2021; 12():658314. PubMed ID: 34012442
[TBL] [Abstract] [Full Text] [Related]
4. How to Treat High-Risk Myeloma at Diagnosis and Relapse.
Caro J; Al Hadidi S; Usmani S; Yee AJ; Raje N; Davies FE
Am Soc Clin Oncol Educ Book; 2021 Mar; 41():291-309. PubMed ID: 34010042
[TBL] [Abstract] [Full Text] [Related]
